Ultra-LEAF™ Purified Human IgG4 Isotype Control Recombinant Antibody

Product Details

Antibody Type

Recombinant

Host Species

Human

Formulation

0.2 µm filtered in phosphate-buffered solution, pH 7.2, containing no preservative.

Endotoxin Level

Less than 0.01 EU/µg of the protein (< 0.001 ng/µg of the protein) as determined by the LAL test.

Preparation

The Ultra-LEAF™ (Low Endotoxin, Azide-Free) antibody was purified by affinity chromatography.

Concentration

The antibody is bottled at the concentration indicated on the vial, typically between 2 mg/mL and 3 mg/mL. Older lots may have also been bottled at 1 mg/mL. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.

Storage & Handling

The antibody solution should be stored undiluted between 2°C and 8°C. This Ultra-LEAF™ solution contains no preservative; handle under aseptic conditions.

Application

FC - Quality tested
Elisa Control - Verified 

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis as negative control. Use at concentrations comparable to those of the specific antibody of interest.

Application Notes

QA16A15 is a recombinant human IgG4. It can be used as an isotype control when evaluating fully human, humanized, or chimeric antibodies. This product is suitable as an isotype-matched control for ELISA, immunoblotting, FACS, IHC, and functional studies.

Product Citations

1. Junker F, et al. 2021. Cytometry A. 99:832. PubMed
2. Roberts A, et al. 2021. Sci Rep. 11:4030. PubMed
3. Mandel I, et al. 2022. J Immunother Cancer. 10:. PubMed
4. Sasaki T, et al. 2020. Int Immunol. 163:32. PubMed
5. Assi HH, et al. 2021. Cancer Immunol Res. 9:1451. PubMed
6. Takele Y, et al. 2022. PLoS Negl Trop Dis. 16:e0010544. PubMed
7. Tahir S, et al. 2021. MAbs. 13:1961349. PubMed
8. Phakham T, et al. 2021. Front Plant Sci. 12:736299. PubMed
9. Fassler M, et al. 2021. J Neuroinflammation. 18:19. PubMed
10. Thakkar D, et al. 2022. J Immunother Cancer. 10:. PubMed
11. Smalley M, et al. 2020. iScience. 23:101229. PubMed

Antigen Details

Structure

Immunoglobulin, 150 KDa

Cell Type

B cells

Biology Area

Immunology

Gene ID

NA

Documentation

• Technical Data Sheet (pdf)
• Certificate of Analysis
• Material Safety Data Sheet

Reviews

Related Pages & Pathways

Related FAQs

Do you guarantee that your antibodies are totally pathogen free?

BioLegend does not test for pathogens in-house aside from the GoInVivo™ product line. However, upon request, this can be tested on a custom basis with an outside, independent laboratory.

Does BioLegend test each Ultra-LEAF™ antibody by functional assay?

No, BioLegend does not test Ultra-LEAF™ antibodies by functional assays unless otherwise indicated. Due to the possible complexities and variations of uses of biofunctional antibodies in different assays and because of the large product portfolio, BioLegend does not currently perform functional assays as a routine QC for the antibodies. However, we do provide references in which the antibodies were used for functional assays and we do perform QC to verify the specificity and quality of the antibody based on our strict specification criteria.

Does BioLegend test each Ultra-LEAF™ antibody for potential pathogens?

No, BioLegend does not test for pathogens in-house unless otherwise indicated.  However, we can recommend an outside vendor to perform this testing as needed.

Have you tested this Ultra-LEAF™ antibody for in vivo or in vitro applications?

We don't test our antibodies for in vivo or in vitro applications unless otherwise indicated. Depending on the product, the TDS may describe literature supporting usage of a particular product for bioassay. It may be best to further consult the literature to find clone specific information.

Other Formats

Certificate of Analysis